医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917

2022年12月07日 PM03:11
このエントリーをはてなブックマークに追加


 

TOKUSHIMA, Japan

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML).

Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval.

DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon.

Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families.

Company profile

Company name

Delta-Fly Pharma, Inc. [Tokyo:4598]

Capital

3352 million Japanese Yen

Name and Title of Representative

Kiyoshi Eshima, PhD, President

Date of Incorporation

December 6, 2010

Description of Business

Research and development, manufacturing and marketing of pharmaceuticals

Head Office

37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan

Branch Office

Tokyo, Beijing, Vancouver

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206006153/en/

CONTACT

Delta-Fly Pharma, Inc.

Inquiries: Yasuo Matsueda

TEL: +81-(0)3-6231-1278

ymatsueda1206@delta-flypharma.co.jp

https://www.delta-flypharma.co.jp/en/

同じカテゴリーの記事 

  • Bio-Sourcing及其合作伙伴利用190万欧元的EUREKA Eurostars补贴启动价值340万欧元的欧盟炎症适应症项目
  • TVM Capital Healthcare宣布聚焦沙特阿拉伯的TVM Healthcare Afiyah Fund结束募资
  • TVMキャピタル・ヘルスケア、 サウジアラビア特化の「TVMヘルスケア・アフィア・ファンド」のクロージングを発表
  • RevolKa Signed Master Service Agreement with Daiichi Sankyo
  • 在TROPION-Lung01 III期试验中,与化疗相比,Datopotamab deruxtecan对晚期非鳞状非小细胞肺癌患者总生存期的改善具有临床意义